Page 2 - Lupin Ltd News

Stocks to Watch today, Feb 25: RIL, Schaeffler, Aditya Infotech, Hindalco

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to Watch today, Feb 17: Cochin Shipyard, JSW Infra, Lupin, Seamec

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Analyst at Kotak Sec bets on ICICI Bank, Lupin

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

Lupin rises post-Q3 analysts call, but brokerages flag FY27 earnings risk

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

Stocks to Watch today: Bharti Airtel, LIC, Trent, NSDL, Tata Power, Marico

Stocks to Watch today, February 5, 2026: Medanta, JSW Cement, Cummins India, Emcure Pharma, Bajaj Finserv, Metropolis, Emami, Lupin, and NHPC are among the top stocks to watch today

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Nifty seen in tight range; BSE, Lupin among Ajit Mishra's stock picks

Nifty prediction today: Continued profit booking and earnings-related reactions in select heavyweights may limit the pace of any immediate recovery in Nifty, said Ajit Mishra of Religare Broking.

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Lupin signs exclusive India pact with Gan & Lee for fortnightly GLP-1 drug

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle

Stocks to Watch today, Nov 17: Maruti Suzuki, Ola Electric, Marico, Lupin

Stocks to Watch Today, November 17, 2025: Marico, Glenmark Pharma, FirstCry, Siemens, Dish TV, Alembic Pharma, Cyient, and Websol Energy System are among the top stocks to remain in focus today

Trading guide: Nifty eyes 26,000; CDSL, Lupin, Nestle on analyst radar

Ajit Mishra, SVP-Research at Religare Broking, has recommended buying CDSL, Nestle India, and Lupin stocks today. Check key rationales here

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Stocks to Watch today, Nov 7: Bharti Airtel, LIC, Lupin, Bajaj Housing

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today

Lupin Q2 PAT rises 73% on strong growth across key global markets

Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix